Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation.

Diabetic medicine : a journal of the British Diabetic Association - 1 Mar 2008

Slingerland A S, Hurkx W, Noordam K, Flanagan S E, Jukema J W, Meiners L C, Bruining G J, Hattersley A T, Hadders-Algra M

Abstract excerpt

BACKGROUND: KCNJ11 mutations are a common cause of diabetes diagnosed in the first 6 months of life, and approximately 25% of patients have neurological features. Sulphonylureas have been shown to improve glycaemic control and also motor function, but the impact on cognitive function has not been extensively addressed previously. METHODS: The patient had a low birth weight and was found to have diabetes at the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain
Share to Cognition

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Developmental Disabilities

Share to Diabetes Mellitus

Share to Genetic Predisposition to Disease

Share to Infant, Newborn

Share to Potassium Channels, Inwardly Rectifying

Share to Sulfonylurea Compounds

Source

Identifiers

PMID: 18307455
DOI: 10.1111/j.1464-5491.2007.02373.x

Genes

KCNJ11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation.PMID 18307455Read ↗

Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene.Semantic proximity Read ↗

Sulfonylurea for improving neurological features in neonatal diabetes: A systematic review and meta-analyses.Semantic proximity Read ↗

Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11Semantic proximity Read ↗

Intellectual Disability in KATP Channel Neonatal Diabetes.Semantic proximity Read ↗

The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy.Semantic proximity Read ↗

Visuomotor performance in KCNJ11-related neonatal diabetes is impaired in children with DEND-associated mutations and may be improved by early treatment with sulfonylureas.Semantic proximity Read ↗

A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain.Semantic proximity Read ↗

Long-term Follow-up of Glycemic and Neurological Outcomes in an International Series of Patients With Sulfonylurea-Treated ABCC8 Permanent Neonatal Diabetes.Semantic proximity Read ↗

Patients with <i><scp>KCNJ</scp>11</i>‐related diabetes frequently have neuropsychological impairments compared with sibling controlsSemantic proximity Read ↗

Sulfonylurea Therapy Benefits Neurological and Psychomotor Functions in Patients With Neonatal Diabetes Owing to Potassium Channel Mutations.Semantic proximity Read ↗

DEND Syndrome with Heterozygous KCNJ11 Mutation Successfully Treated with Sulfonylurea.Semantic proximity Read ↗

Successful transition to sulfonylurea in neonatal diabetes, developmental delay, and seizures (DEND syndrome) due to R50P KCNJ11 mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.